GLPwatch
Papers (10382)
Page 110 of 174, ranked by citation count.
- Dulaglutide Shows Sustained Reduction in Glycosylated Hemoglobin Values: 2-Year US Real-world Study Results.
- Enhancing bile tolerance of Lactobacilli is involved in the hypolipidemic effects of liraglutide.
- Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-world Setting.
- Prehospital exenatide in hyperglycemic stroke-A randomized trial.
- Separation by hydrophobic interaction chromatography and structural determination by mass spectrometry of mannosylated glycoforms of a recombinant transferrin-exendin-4 fusion protein from yeast.
- Comparison of the injection-site experience of the starting doses with semaglutide and dulaglutide: A randomized, double-blind trial in healthy subjects.
- Additive Effects of Exenatide, Glucose-insulin-potassium, and Remote Ischemic Conditioning Against Reperfusion Ventricular Arrhythmias in Pigs.
- Ameliorative Impact of Liraglutide on Chronic Intermittent Hypoxia-Induced Atrial Remodeling.
- Utilising Health Technology Assessment to Develop Managed Access Protocols to Facilitate Drug Reimbursement in Ireland.
- Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
- Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado.
- Liraglutide for Adolescents with Obesity.
- The Impact of Substantial Improvements in HbA1c and Weight Loss on the Medication Preferences of People with Type 2 Diabetes.
- Rhabdomyolysis Associated with the Use of Tirzepatide.
- [Liraglutide attenuates myocardial ischemia/reperfusion injury possibly through reducing cardiomyocytes apoptosis and oxidation in rats].
- Liraglutide suppresses ferroptosis by upregulation NRF2 in type 2 diabetic cardiomyopathy.
- Tirzepatide, a dual GIP/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide.
- Structural study of an active analog of EX-4 in solution and micelle associated states.
- Evaluating the Efficacy and Safety of Tirzepatide on Glycaemic and Non-glycaemic Outcomes in Diabetes: A Systematic Review of Meta-Analyses.
- Real-world safety comparison of liraglutide and semaglutide in weight management: Insights from European pharmacovigilance data.
- Effects of once-weekly glucagon-like peptide-1 receptor agonists on type 2 diabetes mellitus complicated with coronary artery disease: Potential role of the renin-angiotensin system.
- Maternal Weight Intervention in the Perinatal Period Improves Liver Health in the Offspring of Mothers with Obesity.
- Pharmacokinetic properties and effects of PT302 after repeated oral glucose loading tests in a dose-escalating study.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Exenatide alters absorption of hydrocortisone in a diabetic patient with panhypopituitarism: iatrogenic adrenal insufficiency.
- A case for screening real-world data for collateral drug benefits: Glucagon-like peptide 1 receptor agonists and bile acid diarrhea.
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- Liraglutide for Adolescents with Obesity.
- Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with OUD: a randomized, double-blind, placebo-controlled clinical trial protocol.
- Cardiovascular safety outcomes of new antidiabetic therapies.
- Impact of lixisenatide dose range on clinical outcomes with fixed-ratio combination iGlarLixi in patients with type 2 diabetes.
- Comparative clinical outcomes of adults with obstructive sleep apnea and comorbid obesity receiving tirzepatide versus bariatric metabolic surgery: A Multi-Institutional propensity score matched study.
- Dapagliflozin plus exenatide on patients with type 2 diabetes awaiting bariatric surgery in the DEXBASU study.
- Liraglutide for weight loss in obese people.
- Efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes: The Soli-SWITCH study.
- A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes.
- Long-term cost-effectiveness of tirzepatide for individuals with type 2 diabetes and comorbid obesity.
- Efficacy and Safety of Dulaglutide Compared to Liraglutide: A Systematic Review and Meta-analysis in Patients with Type 2 Diabetes Mellitus.
- Pancreatic Safety of Tirzepatide and Its Effects on Islet Cell Function: A Systematic Review and Meta-Analysis.
- Association between eating behavior patterns and the therapeutic efficacy of GLP-1 receptor agonists in individuals with type 2 diabetes: a multicenter prospective observational study.
- WHO Warns of Counterfeit Ozempic in the Global Supply Chain-Here's What to Know.
- Lack of Benefit for Liraglutide in Heart Failure-Reply.
- Sodium glycocholate liposome encapsulated semaglutide increases oral bioavailability by promoting intestinal absorption.
- Exendin-4 Exacerbates Burn-Induced Morbidity in Mice by Activation of the Sympathetic Nervous System.
- CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.
- Exendin-4, a glucagon-like peptide-1 receptor agonist, regulates ductus arteriosus by vasodilation and anti-remodeling through the PKA pathway.
- Comparative efficacy and safety of antidiabetic agents in Alzheimer's disease: A network meta-analysis of randomized controlled trials.
- Defining Clinically Relevant Target Populations Using Real-World Data to Guide the Design of Representative Antidiabetic Drug Trials.
- Improving glycemic control: transitioning from dulaglutide to tirzepatide in patients with type 2 diabetes undergoing hemodialysis.
- A systematic review of the economic value proposition for commercially available nonsurgical weight-loss interventions.
- The GLP-1 Receptor Agonist Dulaglutide Attenuates Hepatic Steatosis in Obesity via a Weight-Independent Mechanism.
- Treatment of obesity: will incretin agonists make bariatric surgery a thing of the past?
- Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a national cohort study.
- Liraglutide for the Treatment of Obesity: Analyzing Published Reviews.
- Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review.
- NPYR modulation: Potential for the next major advance in obesity and type 2 diabetes management?
- Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon.
- Triple-Hormone Combination Retatrutide Induces 24% Body Weight Loss.
- Patient involvement in drug licensing: a case study.
- Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care-a systematic review and network meta-analysis.